Other co-occurring mutations in classic NSCLC oncogenic drivers, including EGFR L858R (n=1), MET amplification (n = 1), and KRAS G12D (n = 4), were detected from tissue samples of 6 patients. This evidence concerns the gene MET and non-small cell lung carcinoma.